{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:31Z","timestamp":1790270731356,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijgc.2025.102715","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:56:47Z","timestamp":1763186207000},"page":"102715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Olaparib dose reduction in BRCA-mutated platinum-sensitive ovarian cancer recurrence: real-world data"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4677-469X","authenticated-orcid":false,"given":"Serena Maria","family":"Boccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4372-4220","authenticated-orcid":false,"given":"Matteo","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3602-2635","authenticated-orcid":false,"given":"Camilla","family":"Culcasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenza","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1702-5859","authenticated-orcid":false,"given":"Carolina Maria","family":"Sassu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vertechy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4614-9261","authenticated-orcid":false,"given":"Adriana Ionelia","family":"Apostol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1233-9850","authenticated-orcid":false,"given":"Giorgia","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2025.102715_bib1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2017.04.011","article-title":"Impact of primary platinum-free interval and BRCA1\/2 mutation status on treatment and survival in patients with recurrent ovarian cancer","volume":"146","author":"Bookman","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102715_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103627","article-title":"HRD testing for all advanced high-grade ovarian carcinoma in first line?","volume":"9","author":"Puglisi","year":"2024","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102715_bib3","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102715_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103984","article-title":"Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights","volume":"9","author":"Tuninetti","year":"2024","journal-title":"ESMO Open"},{"issue":"15","key":"10.1016\/j.ijgc.2025.102715_bib6","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102715_bib8","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102715_bib9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.annonc.2022.02.222","article-title":"The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2\/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer","volume":"33","author":"Francis","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102715_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102715_bib11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1634\/theoncologist.2017-0485","article-title":"Administration of the tablet formulation of olaparib in patients with ovarian cancer: practical guidance and expectations","volume":"23","author":"Moore","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ijgc.2025.102715_bib12","unstructured":"European Medicines Agency. Lynparza (olaparib) 100 mg and 150 mg film-coated tablets: summary of Product Characteristics. EMA EPAR. Accessed June 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf."},{"issue":"3","key":"10.1016\/j.ijgc.2025.102715_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157339406777934717","article-title":"Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy","volume":"2","author":"Wang","year":"2006","journal-title":"Curr Cancer Ther Rev"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102715_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s11523-018-0604-z","article-title":"Real-world use and outcomes of olaparib: a population-based cohort study","volume":"13","author":"Eriksson","year":"2018","journal-title":"Target Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102715_bib16","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102715_bib17","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1136\/ijgc-2024-005363","article-title":"Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients","volume":"34","author":"Bruno","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"25","key":"10.1016\/j.ijgc.2025.102715_bib18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ijgc.2025.102715_bib19","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102715_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/diagnostics9030087","article-title":"Combined strategies with poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review","volume":"9","author":"Boussios","year":"2019","journal-title":"Diagnostics (Basel)"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102715_bib21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br J Cancer"},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2025.102715_bib22","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.2021.39.15_suppl.5505","article-title":"EFFORT: EFFicacy of adavosertib in PARP ResisTance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer","volume":"39","author":"Westin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102715_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100099","article-title":"Association between BRCA1 and BRCA2 mutations with toxicity from olaparib in platinum-sensitive relapsed high grade ovarian cancer","volume":"35","author":"Russo","year":"2025","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25018353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25018353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:29:30Z","timestamp":1776346170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25018353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1048891X25018353"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102715","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olaparib dose reduction in BRCA-mutated platinum-sensitive ovarian cancer recurrence: real-world data","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102715"}}